Navigation Links
EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
Date:11/9/2010

antly, both in the U.S. and further afield. In the coming months, EUSA plans to achieve pan-European authorization for ERWINASE, and our partners are pursuing regulatory approval in Japan and elsewhere. As a result, ERWINASE has the opportunity to become EUSA's second global product, marking the company's rapid transformation into a leading player in the specialty oncology field."

About acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most commonly diagnosed childhood cancer [1]. ALL predominantly affects children and adolescents, who account for over 60% of the more than 5,000 new cases diagnosed in the U.S. each year [2]. ALL treatment is complex, involving a number of stages and many drugs, and includes asparaginase as an essential component of current protocols. Pediatric treatment is often highly successful, with remission rates of over 95% and 75 - 85% of treated children surviving for at least five years without recurrence of leukemia [1].

About ERWINASE

ERWINASE is an asparaginase enzyme that depletes the level of the amino acid asparagine in the bloodstream. Asparagine is essential for cell growth, and its removal from the blood inhibits the growth of cells associated with acute lymphoblastic leukemia. Asparaginase products are derived from bacteria, and up to 60% of patients develop antibodies to those produced by Escherichia coli [3]. ERWINASE, which is produced by Erwinia chrysanthemi, is immunologically distinct from these therapies and is suitable for patients with hypersensitivity to E. coli-derived treatments*. The BLA submission for ERWINASE includes data from a recent study in children with hypersensitivity to pegylated E. coli asparaginase, which will be presented at the American Society of Hematology in December 2010.

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage onc
'/>"/>

SOURCE EUSA Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
2. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
3. How IT Helps Solve Pharmas R&D Problems: in silico Drug Discovery
4. UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth
5. Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas
6. Tianyin Pharmaceutical Co., Inc. to Host First Quarter of Fiscal Year 2011 Earnings Conference Call on Thursday, November 11, 2010 at 9:00 a.m. ET
7. ShangPharma Announces Appointment of Benson Tsang as a Member of the Board of Directors and Audit Committee
8. NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
9. WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility
10. EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist
11. Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... China Nepstar Chain Drugstore Ltd. (NYSE: NPD ) ... in China based on the number of directly operated ... second quarter ended June 30, 2015. Financial ... Revenue increased by 12.9% to RMB775.1 million (US$125.0 million) ... 2014 , Same store sales increased by 16.7% ...
(Date:9/1/2015)... Delaware , United States ... "Company" or "Invion"), is pleased to announce that it has ... an institutional investor in the United States ... approximately A$1.001 million ("Placement") by the issue of 71,500,000 million ... per share. The Company has also agreed ...
(Date:9/1/2015)... BRUSSELS , Sept. 1, 2015 /PRNewswire/ ... Brussels: UCB) today announced top-line results from the ... with Teriparatide in postmenopaUsal women with osteoporosis at ... therapy). The study (NCT01796301) met the primary endpoint, ... romosozumab in the percent change of total hip ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 10Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9
... from Phase II/III Study Presented at Heart Failure Congress ... , SAN MATEO¿ Calif.¿ June 1 Corthera Inc. ... conducted from Pre-RELAX-AHF, the Phase II portion of a ... relaxin, the company,s investigational drug for the treatment of ...
... ORLANDO, Fla., May 31 Eli Lilly and Company ... addition of Lilly,s GEMZAR(R) (gemcitabine HCl for injection) to ... increase in progression-free survival at three years for women ... the world,s second most commonly diagnosed women,s cancer, and ...
Cached Medicine Technology:Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables 2Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables 3Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables 4Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 2Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 3Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 4Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 6
(Date:9/2/2015)... ... 2015 , ... Pentec Health, Inc., a national leader in outsourced pharmacy services, ... consecutive year. Less than 5 % of this year’s 5000 honorees share the “six-time” ... Pentec’s 3-year revenue growth rate of 65% sustained its most recent achievement. As an ...
(Date:9/2/2015)... ... September 02, 2015 , ... Dr. Robert G. ... he is now certified in “Systema”: a Russian martial art system that is also ... , Systema , which dates back to the 10th century, is a ...
(Date:9/2/2015)... ... September 02, 2015 , ... Mobile working is increasingly more important, as business ... everywhere new mobile apps are being launched, and mobile device usage as a whole ... of their work and personal lives. What's more people are expecting mobile versions of ...
(Date:9/1/2015)... Spring Lake, NJ (PRWEB) , ... September 01, ... ... physician, has a reputation for the telling the truth about medicine and health, ... has created a video blog, where he plans to regularly debunk certain misconceptions ...
(Date:9/1/2015)... Paul- Eagan (PRWEB) , ... September 01, 2015 , ... For many men, the first ... chin. Men were often forced to wear a looser fitting shirt with a collar ... their neck, sliding a finger between their collar and skin all day because it’s uncomfortable. ...
Breaking Medicine News(10 mins):Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 3Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:Dr. Michael Rothman, NJ’s Leading Holistic Doctor, Presents a Video Blog that Discusses the Most Confusing and Interesting Current Medical Topics 2Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2
... excess weight worsens disease , THURSDAY, June 4 (HealthDay News) ... as many experts have thought, but it could dampen the ... , Inhaled corticosteroids are the most widely prescribed drugs to ... whom are overweight or obese. , "It raises the concern ...
... N.J., June 4 Cambrex Corporation (NYSE: CBM ... New York Stock Exchange ("NYSE") informing the Company that it ... As announced by the Company on April 14, 2009, ... standards because its average market capitalization over a consecutive 30-day ...
... night, the America,s Health Insurance Plans (AHIP) Foundation paid ... Group Health Cooperative of South Central Wisconsin, and L.A. ... designed to improve the health and environment of communities ... health plans of working with local partners in a ...
... , "Headache U" is first educational program of its kind, matches ... , CHICAGO, June 4 The National Headache Foundation (NHF) ... headache education program of its kind designed to help people with ... beginning today on the NHF website at http://www.headaches.org/headacheu/ ...
... , MIAMI, June 4 St. Jude Children,s Research Hospital(R) ... by honoring Tommy and Thalia Mottola on May ... Estefan , co-host of the popular Univision show El ... the 2009 Al-Rashid Hope Award for their commitment to children,s ...
... could lead to treatment or prevention , THURSDAY, June 4 ... a key role in cell death in Huntingdon,s disease, a ... intellectual functioning. , The discovery raises hope that drugs could ... a study in the June 5 issue of Science ...
Cached Medicine News:Health News:Obesity May Dampen Response to Asthma Meds 2Health News:AHIP Foundation Announces 2009 Community Leadership Awards 2Health News:New Online Tool Helps People With Headache Take Control, Get Relief 2Health News:New Online Tool Helps People With Headache Take Control, Get Relief 3Health News:New Online Tool Helps People With Headache Take Control, Get Relief 4Health News:Photos: Tommy & Thalia Mottola Honored at 7th Annual FedEx/St. Jude Angels & Stars Gala 2Health News:Photos: Tommy & Thalia Mottola Honored at 7th Annual FedEx/St. Jude Angels & Stars Gala 3Health News:Discovery Sheds Light on Huntington's Disease 2Health News:Discovery Sheds Light on Huntington's Disease 3
... standard, corrected curve trial lenses are ground with ... Marco refractors and are invaluable in treating low ... other manufacturers contain a disproportionately large number of ... expensive to produce, and fewer lenses in the ...
The LM-990A is the most completely automatic lensemeter ever created. It even measured monocular and binocular PD automatically....
... has made the LM-770 the easiest ... Technicians can be trained to operate ... instruction. The instrument tells the user ... A flashing indicator alerts the user ...
... designed to perform precise and accurate ... one-third the space of traditional examinations. ... refractors, automatic or digital lensmeters and ... EPIC enables the operator to call ...
Medicine Products: